Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.K. (FTSE) Pharma Industry Analysis

UpdatedApr 05, 2026
DataAggregated Company Financials
Companies15
  • 7D6.0%
  • 3M13.3%
  • 1Y36.6%
  • YTDn/a

Over the last 7 days, the Pharma industry has risen 6.0%, driven by gains from AstraZeneca of 7.1%. In the last 12 months, the industry was up 37%. Looking forward, earnings are forecast to grow by 10% annually.

Industry Valuation and Performance

Has the U.K. Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 05 Apr 2026UK£362.2bUK£91.4bUK£15.7b20x23x4x
Tue, 03 Mar 2026UK£370.6bUK£90.4bUK£15.6b22.7x23.8x4.1x
Thu, 29 Jan 2026UK£321.3bUK£88.3bUK£14.4b22.4x22.3x3.6x
Sat, 27 Dec 2025UK£323.1bUK£89.3bUK£14.6b21.8x22.2x3.6x
Mon, 24 Nov 2025UK£325.5bUK£90.6bUK£14.8b22.1x22x3.6x
Wed, 22 Oct 2025UK£298.0bUK£87.9bUK£11.7b20.4x25.4x3.4x
Fri, 19 Sep 2025UK£270.5bUK£87.3bUK£11.7b20.4x23.2x3.1x
Sun, 17 Aug 2025UK£275.2bUK£87.3bUK£11.7b21.9x23.6x3.2x
Tue, 15 Jul 2025UK£262.7bUK£86.7bUK£10.7b25.5x24.7x3x
Thu, 12 Jun 2025UK£273.8bUK£86.3bUK£10.6b27.2x25.8x3.2x
Sat, 10 May 2025UK£258.5bUK£87.2bUK£10.7b26.3x24.2x3x
Mon, 07 Apr 2025UK£266.5bUK£87.9bUK£9.7b30.7x27.4x3x
Wed, 05 Mar 2025UK£294.1bUK£88.4bUK£9.7b29.9x30.3x3.3x
Fri, 31 Jan 2025UK£239.2bUK£75.8bUK£7.8b33.6x30.6x3.2x
Sun, 29 Dec 2024UK£224.3bUK£75.3bUK£7.8b31.4x28.9x3x
Tue, 26 Nov 2024UK£225.0bUK£75.4bUK£7.8b31.4x28.9x3x
Thu, 24 Oct 2024UK£250.5bUK£72.7bUK£9.1b30.3x27.6x3.4x
Sat, 21 Sep 2024UK£252.7bUK£71.5bUK£8.9b37.8x28.3x3.5x
Mon, 19 Aug 2024UK£275.1bUK£72.6bUK£9.0b40.7x30.4x3.8x
Wed, 17 Jul 2024UK£256.4bUK£70.7bUK£9.4b35.1x27.2x3.6x
Fri, 14 Jun 2024UK£266.6bUK£71.3bUK£9.6b32x27.9x3.7x
Sun, 12 May 2024UK£273.5bUK£72.1bUK£9.6b37.4x28.4x3.8x
Tue, 09 Apr 2024UK£240.2bUK£70.7bUK£9.7b31.9x24.8x3.4x
Thu, 07 Mar 2024UK£234.3bUK£70.4bUK£9.7b30.5x24.1x3.3x
Sat, 03 Feb 2024UK£237.3bUK£69.8bUK£9.5b35.2x24.9x3.4x
Mon, 01 Jan 2024UK£235.0bUK£68.8bUK£10.7b35.5x22.1x3.4x
Wed, 29 Nov 2023UK£222.3bUK£68.9bUK£10.7b33.5x20.8x3.2x
Fri, 27 Oct 2023UK£234.7bUK£70.9bUK£10.4b54.2x22.6x3.3x
Sun, 24 Sep 2023UK£247.8bUK£70.5bUK£10.4b56.6x23.9x3.5x
Tue, 22 Aug 2023UK£234.0bUK£68.9bUK£10.2b53.5x23.1x3.4x
Thu, 20 Jul 2023UK£231.7bUK£67.2bUK£7.8b52x29.6x3.4x
Sat, 17 Jun 2023UK£251.8bUK£67.5bUK£7.9b55.5x32x3.7x
Mon, 15 May 2023UK£259.2bUK£68.6bUK£8.0b59.3x32.5x3.8x
Wed, 12 Apr 2023UK£253.2bUK£69.3bUK£6.9b53.5x36.9x3.7x
Price to Earnings Ratio

36.9x


Total Market Cap: UK£253.2bTotal Earnings: UK£6.9bTotal Revenue: UK£69.3bTotal Market Cap vs Earnings and Revenue0%0%0%
U.K. Pharma Industry Price to Earnings3Y Average 26.1x202420252026
Current Industry PE
  • Investors are pessimistic on the British Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 23.0x which is lower than its 3-year average PE of 26.1x.
  • The 3-year average PS ratio of 3.4x is lower than the industry's current PS ratio of 4.0x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 32% per year over the last three years.
  • Revenues for these companies have grown 9.7% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Comparison

How does U.K. Pharma compare with similar industries?

GB Market4.54%
Healthcare5.69%
Pharma5.96%
Pharma5.96%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
AZN AstraZenecaUK£153.167.1%
+UK£15.7b		41.7%PE30.7x
GSK GSKUK£21.444.6%
+UK£3.8b		51.3%PE15x
HLN HaleonUK£3.731.6%
+UK£496.1m		-2.8%PE20x
HCM HUTCHMED (China)UK£2.1911.2%
+UK£189.1m		-2.0%PE5.4x
HIK Hikma PharmaceuticalsUK£13.085.2%
+UK£129.6m		-30.3%PE9.3x

Latest News

GSK
UK£21.44
GSK
7D
4.6%
1Y
51.3%

GSK: Limited Pipeline Readouts Will Continue To Cap Future Multiple Repricing

GSK's analyst price target has moved higher by £100, with analysts pointing to slightly stronger long term revenue growth and profit margin assumptions, alongside modestly lower future P/E expectations. Analyst Commentary Recent research on GSK reflects a mix of higher price targets and ongoing caution around the company’s execution and growth profile.
STX
UK£0.086
Shield Therapeutics
7D
7.5%
1Y
218.5%

STX: Pediatric And China Approvals Will Expand Future Earnings Power

Analysts have maintained their fair value estimate for Shield Therapeutics at £0.14. The discount rate remains unchanged, and updated assumptions for revenue growth, profit margin and future P/E support the latest price target view.
EAH
UK£0.92
ECO Animal Health Group
7D
-6.1%
1Y
75.2%
AGY
UK£0.10
Allergy Therapeutics
7D
-1.0%
1Y
59.7%
HIK
UK£13.08
Hikma Pharmaceuticals
7D
5.2%
1Y
-30.3%

HIK: Buyback Plan And Leadership Changes Will Support Future Re Rating

Hikma Pharmaceuticals' updated fair value estimate has edged down slightly to £19.02 per share from £19.06. This reflects a series of reduced analyst price targets between £1,600 and £2,000, along with their increased focus on management uncertainty, strategic direction, and a more conservative P/E outlook.
AZN
UK£153.16
AstraZeneca
7D
7.1%
1Y
41.7%
HCM
UK£2.19
HUTCHMED (China)
7D
11.2%
1Y
-2.0%

HCM: Advancing Late Stage Oncology Pipeline Will Drive Future Reassessment

Analysts have nudged their fair value estimate for HUTCHMED (China) higher to £5.62 from £5.34, citing updated assumptions on discount rate, revenue growth, profit margin and future P/E that have slightly adjusted their overall outlook. What's in the News Initiated a registrational Phase III trial of BTK inhibitor HMPL-760 with R-GemOx in relapsed or refractory diffuse large B-cell lymphoma in China, targeting about 240 patients and using progression free survival and overall survival as primary outcomes (Product-Related Announcement).
HLN
UK£3.73
Haleon
7D
1.6%
1Y
-2.8%

HLN: Execution And Cash Returns Will Support Future Re Rating Potential

Haleon's analyst price target has been nudged up from £5.10 to £5.12, reflecting analysts' updated assumptions for slightly higher revenue growth and profit margins, together with recent target increases and rating changes across several research houses. Analyst Commentary Recent Street research on Haleon has been active, with several bullish analysts adjusting their targets and ratings while one major European house turned more cautious.
FUM
UK£0.011
Futura Medical
7D
-4.7%
1Y
-88.4%
NFX
UK£0.0018
Nuformix
7D
-2.8%
1Y
44.6%
SAR
UK£0.15
Sareum Holdings
7D
-3.1%
1Y
3.3%
INC
UK£0.01
Incanthera
7D
-50.0%
1Y
-88.2%
ANCR
UK£2.34
Animalcare Group
7D
1.7%
1Y
9.3%
POLB
UK£0.043
Poolbeg Pharma
7D
1.2%
1Y
73.5%